现实世界中的长效注射用丁丙诺啡：双重失调病例报告。

IF 1.6 4区医学 Q3 SUBSTANCE ABUSE

Journal of Addictive Diseases Pub Date : 2024-05-21 DOI:10.1080/10550887.2024.2354566

Raul Felipe Palma-Alvarez, Germán Ortega-Hernández, Maria Roch-Santed, Josep Antoni Ramos-Quiroga, Lara Grau-López

{"title":"现实世界中的长效注射用丁丙诺啡：双重失调病例报告。","authors":"Raul Felipe Palma-Alvarez, Germán Ortega-Hernández, Maria Roch-Santed, Josep Antoni Ramos-Quiroga, Lara Grau-López","doi":"10.1080/10550887.2024.2354566","DOIUrl":null,"url":null,"abstract":"Objectives: Long-acting injectable buprenorphine (LAIB) has demonstrated a good profile for opioid use disorder (OUD) management. However, there is scarce information on LAIB in OUD patients with comorbid mental disorders (dual disorder patients).Methods: We present a case report on OUD patients with a comorbid mental disorder who have received LAIB for at least 3 months.Results: Two women and one man with OUD and another comorbid mental disorder were prescribed with LAIB ranging from three to twelve months. Good adherence and opioid abstinence were observed during the follow-up. Psychopathological issues related to comorbid mental disorders were stabilized. A deep discussion on LAIB in this profile of patients is conducted.Conclusions: LAIB in OUD patients with comorbid mental disorders may be a safe and well tolerated option, similar to OUD patients without comorbid mental disorders. LAIB's impact on psychopathological issues requires further high-quality research to understand the real impact of LAIB on OUD and comorbid mental disorders.","PeriodicalId":47493,"journal":{"name":"Journal of Addictive Diseases","volume":" ","pages":"1-7"},"PeriodicalIF":1.6000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-acting injectable buprenorphine in the real world: case report on dual disorders.\",\"authors\":\"Raul Felipe Palma-Alvarez, Germán Ortega-Hernández, Maria Roch-Santed, Josep Antoni Ramos-Quiroga, Lara Grau-López\",\"doi\":\"10.1080/10550887.2024.2354566\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: Long-acting injectable buprenorphine (LAIB) has demonstrated a good profile for opioid use disorder (OUD) management. However, there is scarce information on LAIB in OUD patients with comorbid mental disorders (dual disorder patients).Methods: We present a case report on OUD patients with a comorbid mental disorder who have received LAIB for at least 3 months.Results: Two women and one man with OUD and another comorbid mental disorder were prescribed with LAIB ranging from three to twelve months. Good adherence and opioid abstinence were observed during the follow-up. Psychopathological issues related to comorbid mental disorders were stabilized. A deep discussion on LAIB in this profile of patients is conducted.Conclusions: LAIB in OUD patients with comorbid mental disorders may be a safe and well tolerated option, similar to OUD patients without comorbid mental disorders. LAIB's impact on psychopathological issues requires further high-quality research to understand the real impact of LAIB on OUD and comorbid mental disorders.\",\"PeriodicalId\":47493,\"journal\":{\"name\":\"Journal of Addictive Diseases\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Addictive Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10550887.2024.2354566\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Addictive Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10550887.2024.2354566","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}

引用次数: 0

摘要

目标：长效注射用丁丙诺啡（LAIB）在治疗阿片类药物使用障碍（OUD）方面表现良好。然而，有关长效丁丙诺啡治疗合并精神障碍的阿片类药物使用障碍患者（双重障碍患者）的资料却很少：我们对合并精神障碍的阿片类药物使用障碍患者接受 LAIB 治疗至少 3 个月的病例进行了报告：结果：两名女性和一名男性患有 OUD 和另一种合并精神障碍，他们接受了 3 至 12 个月的 LAIB 治疗。在随访期间观察到了良好的依从性和阿片类药物戒断情况。与合并精神障碍相关的精神病理学问题得到了稳定。本文对LAIB在这类患者中的应用进行了深入探讨：结论：对于合并精神障碍的 OUD 患者，LAIB 可能是一种安全且耐受性良好的选择，这一点与无合并精神障碍的 OUD 患者类似。LAIB对精神病理学问题的影响需要进一步的高质量研究，以了解LAIB对OUD和合并精神障碍的真正影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Long-acting injectable buprenorphine in the real world: case report on dual disorders.

Objectives: Long-acting injectable buprenorphine (LAIB) has demonstrated a good profile for opioid use disorder (OUD) management. However, there is scarce information on LAIB in OUD patients with comorbid mental disorders (dual disorder patients).

Methods: We present a case report on OUD patients with a comorbid mental disorder who have received LAIB for at least 3 months.

Results: Two women and one man with OUD and another comorbid mental disorder were prescribed with LAIB ranging from three to twelve months. Good adherence and opioid abstinence were observed during the follow-up. Psychopathological issues related to comorbid mental disorders were stabilized. A deep discussion on LAIB in this profile of patients is conducted.

Conclusions: LAIB in OUD patients with comorbid mental disorders may be a safe and well tolerated option, similar to OUD patients without comorbid mental disorders. LAIB's impact on psychopathological issues requires further high-quality research to understand the real impact of LAIB on OUD and comorbid mental disorders.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Addictive Diseases SUBSTANCE ABUSE-

CiteScore

4.30

自引率

4.30%

发文量

期刊介绍： The Journal of Addictive Diseases is an essential, comprehensive resource covering the full range of addictions for today"s addiction professional. This in-depth, practical journal helps you stay on top of the vital issues and the clinical skills necessary to ensure effective practice. The latest research, treatments, and public policy issues in addiction medicine are presented in a fully integrated, multi-specialty perspective. Top researchers and respected leaders in addiction issues share their knowledge and insights to keep you up-to-date on the most important research and practical applications.